Overview
ARTBIO develops targeted radioligand therapies to treat cancer. Its lead program AB001 has entered first-in-human studies, and two other targets, ABA and ABB, are under development. These therapies use radioligands that bind to tumor cells with high affinity and deliver radiation directly to tumors while minimizing damage to healthy tissue. ARTBIO differentiates itself through a differentiated pipeline, strong collaborations with F Prime and Radforsk, and a team with decades of experience in drug development, aiming to advance cancer therapies from clinical trials to market. The company’s goal is to bring its therapies to healthcare providers and patients, generating revenue through sales and potential licensing as its treatments gain regulatory approval.
Work here?Claim your company
Simplify's take
What believers are saying
- July 29, 2025 raised $132 million from Sofinnova, B Capital, Qatar Investment Authority.
- January 12, 2026 ARTISAN resumed dosing two cohorts, restoring human data generation.
- ARTBIO opened Oslo labs in 2026, expanding specialized radiopharmaceutical R&D capacity and hiring appeal.
What critics are saying
- April 7, 2026 clinical hold exposed process variability in AB001 manufacturing and dosing.
- July 1, 2026 founder CEO Emanuele Ostuni exited; Jonathan Freeman serves as interim chief.
- Sanofi's 2024 PTAB fight and ARTBIO's patent defense threaten exclusivity if claims fall.
What makes ARTBIO unique
- AlphaDirect produces 212Pb locally, reducing isotope bottlenecks and reactor dependence.
- AB001 targets PSMA in mCRPC, matching a validated oncology biomarker with alpha payloads.
- Oslo Science Park labs and distributed manufacturing link research, production, and clinical execution.
Help us improve and share your feedback! Did you find this helpful?